Donanemab exposure‐response in early symptomatic Alzheimer's disease
Alzheimer's & Dementia · 2025-07 · 21 (7)
DOI: 10.1002/alz.70491 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Alzheimer's & Dementia, online erschienen am 16.07.2025. Verfasst von Ivelina Gueorguieva und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Global Pharmacokinetics/Pharmacodymanics/Pharmacometrics, Eli Lilly and Company, Bracknell, Berkshire, UK. Hauptthemen laut MEDLINE: Alzheimer Disease, Antibodies, Monoclonal, Humanized, Plaque, Amyloid. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION These analyses aimed to identify factors impacting donanemab exposure, amyloid plaque, and clinical efficacy in early symptomatic Alzheimer's disease using a population pharmacokinetic/pharmacodynamic (PK/PD) approach. METHODS Analyses included donanemab trial participants (NCT02624778; NCT03367403; NCT04640077; NCT04437511). Dose‐ and exposure‐response relationships were characterized relative to amyloid plaque lowering using indirect response PK/PD and disease progression models. RESULTS Donanemab population PK was described by a biphasic distribution with an estimated terminal elimination half‐life of approximately 12.1 days for a typical participant (72 kg body weight, 1:2560 maximum antidrug antibody [ADA] titer). Amyloid reduction was associated with maintaining median serum donanemab concentrations over 15 µg/mL (95% confidence interval: 8.54, 18.0). After completing active treatment, simulations showed an estimated plaque reaccumulation rate (median, 95% confidence interval) of 2.8 (2.16, 3.11) Centiloids/year. The donanemab disease progression model showed a clear treatment effect. DISCUSSION These donanemab models can inform dosing strategies in future clinical trials. Highlights Weight‐based and flat dosing had similar exposure metrics; flat dosing was adopted. Donanemab exposure was influenced by weight and titer (not clinically relevant). 2.8 Centiloids/year amyloid reaccumulation rate observed upon donanemab treatment completion. Around 30% reduction in disease progression rate on treatment for integrated Alzheimer's Disease Rating Scale (iADRS) and Clinical Dementia Rating Scale‐Sum of Boxes (CDR‐SB).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Global Pharmacokinetics/Pharmacodymanics/Pharmacometrics, Eli Lilly and Company, Bracknell, Berkshire, UK.
- Department of Global Pharmacokinetics/Pharmacodymanics/Pharmacometrics, Eli Lilly and Company, Singapore, Singapore.
- Department of Imaging Medical, Eli Lilly and Company, Indianapolis, Indiana, USA.
- Department of Medical, Eli Lilly and Company, Indianapolis, Indiana, USA.
Förderung
- Eli Lilly and Company
Zitieren
APA
Gueorguieva, I., Chow, K., Chua, L., Shcherbinin, S., Zimmer, J. A., Evans, C. D., Wang, H., Nery, E. S. M., Brooks, D. A., & Sims, J. R. (2025). Donanemab exposure‐response in early symptomatic Alzheimer's disease. Alzheimer's & Dementia, 21(7). https://doi.org/10.1002/alz.70491
Vancouver
Gueorguieva I, Chow K, Chua L, Shcherbinin S, Zimmer JA, Evans CD, et al. Donanemab exposure‐response in early symptomatic Alzheimer's disease. Alzheimer's & Dementia. 2025;21(7). doi:10.1002/alz.70491
BibTeX
@article{Gueorguieva2025,
author = {Gueorguieva, Ivelina and Chow, Kay and Chua, Laiyi and Shcherbinin, Sergey and Zimmer, Jennifer A and Evans, Cynthia D and Wang, Hong and Nery, Emel Serap Monkul and Brooks, Dawn A and Sims, John R},
title = {Donanemab exposure‐response in early symptomatic Alzheimer's disease},
journal = {Alzheimer's & Dementia},
year = {2025},
volume = {21},
number = {7},
doi = {10.1002/alz.70491}
}
EUVIMED